Neurology

A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

"It's a very rich pipeline because [agitation] is a very common and very debilitating symptom in Alzheimer's disease," Grossberg observed.

Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.

Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.

The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.

Nondrug approaches to calming an adult with Alzheimer disease who is agitated should be prioritized over pharmacotherapy, geriatric psychiatrist George Grossberg, MD, counsels.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

The geriatric psychiatrist refers in this interview to agitation in Alzheimer disease, a significant neuropsychiatric symptom that should not be dismissed.

Your daily dose of the clinical news you may have missed.

Michigan Medicine researchers found that at all age levels, women with known/suspected OSA were more likely than men to be diagnosed with dementia.

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

A 25-year study of the Lothian Birth Cohorts found that childhood intelligence, lifestyle factors, and brain health significantly impact cognitive aging and longevity.

Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.

Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.

Your daily dose of the clinical news you may have missed.

The autoinjector delivers a weekly maintenance dose of 360 mg lecanemab for individuals who have completed biweekly treatment initiation by IV infusion.

New data from phase 3 Clarity AD OLE trial show sustained treatment benefit among participants with low baseline tau and brain amyloid with no new safety signals.

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.

Your daily dose of the clinical news you may have missed.

Rifaximin monotherapy may also confer a survival benefit, according to the study, which was awarded ACG Outstanding Research Award in the Liver Category.

Semaglutide significantly reduced risk of a first-time diagnosis of AD in a cohort of more than 1 million, suggesting an opportunity for controlled clinical trials.

FDA-approved early Alzheimer medications should be covered by Medicare and other insurers and made immediately available to all those who will benefit.

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Supported by Otsuka, new research calculated the value of daily hours spent on basic chores and complex tasks required to support a loved one with AD.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Medicare’s restrictive coverage policies are denying patients with early Alzheimer's disease access to novel treatments. And private payers are following suit.